Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)

Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry

(2012) F. Baudo et al.   BLOOD

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

(2012) S. C. Gouw et al.   BLOOD

Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A - a two-centre experience

(2012) M. HOLMSTRÖM et al.   HAEMOPHILIA

Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance

(2012) C. H. MILLER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight

(2011) S. Bjorkman et al.   BLOOD

Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom

(2011) C. R. M. Hay et al.   BLOOD

The principal results of the International Immune Tolerance Study: a randomized dose comparison

(2011) C. R. M. Hay et al.   BLOOD

Parallel use of by-passing agents in haemophilia with inhibitors: a critical review

(2011) Jørgen Ingerslev et al.   BRITISH JOURNAL OF HAEMATOLOGY

A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B

(2011) M. RECHT et al.   HAEMOPHILIA

Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients - long-term follow-up and continuing experience

(2011) G. AUERSWALD et al.   HAEMOPHILIA

A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing

(2011) S. BJÖRKMAN   HAEMOPHILIA

Risk of inhibitor development in mild haemophilia A increases with age

(2011) E. P. MAUSER-BUNSCHOTEN et al.   HAEMOPHILIA

Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors

(2011) A. GRINGERI et al.   HAEMOPHILIA

Concentrate-related inhibitor risk: is a difference always real?

(2011) A. IORIO et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience

(2011) M. KURTH et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies

(2011) L. M. ALEDORT et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII

(2011) L. M. ALEDORT et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Surgery and inhibitor development in hemophilia A: a systematic review

(2011) C. L. ECKHARDT et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors

(2011) Cindy Leissinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery

(2010) Y. Dargaud et al.   BLOOD

Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience

(2010) E. C. RODRIGUEZ-MERCHAN et al.   HAEMOPHILIA

Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units

(2010) P. C. TER AVEST et al.   HAEMOPHILIA

Importance of rapid bleeding control in haemophilia complicated by inhibitors

(2010) E. BERNTORP   HAEMOPHILIA

Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients

(2010) S. C. GOUW et al.   HAEMOPHILIA

Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors

(2010) S. RANGARAJAN et al.   HAEMOPHILIA

Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition

(2010) E. BERNTORP et al.   HAEMOPHILIA

Treatment related factors and inhibitor development in children with severe haemophilia A

(2010) P. S. MACLEAN et al.   HAEMOPHILIA

Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring

(2010) S. BJÖRKMAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review

(2010) A. IORIO et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A

(2010) Giuseppe Lippi et al.   THROMBOSIS AND HAEMOSTASIS

The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series

(2009) L. A. VALENTINO   HAEMOPHILIA

Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa

(2009) H. TAKEDANI et al.   HAEMOPHILIA

The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy

(2009) D. DIMICHELE   HAEMOPHILIA

Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven®] in elective orthopaedic surgery in haemophilic patients with inhibitors

(2009) P. L. F. GIANGRANDE et al.   HAEMOPHILIA

Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006)

(2009) M. CHITLUR et al.   HAEMOPHILIA

Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors

(2009) U. MARTINOWITZ et al.   HAEMOPHILIA

Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic

(2009) P. SALAJ et al.   HAEMOPHILIA

Rituximab and Desensitization for a Patient With Severe Factor IX Deficiency, Inhibitors, and History of Anaphylaxis

(2009) Sarah Alexander et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort

(2009) P. W. COLLINS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Intensive peri-operative use of factor VIII and the Arg593→Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A

(2009) C.L. ECKHARDT et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Inhibitors of Factor VIII in Black Patients with Hemophilia

(2009) Kevin R. Viel et al.   NEW ENGLAND JOURNAL OF MEDICINE

How we treat a hemophilia A patient with a factor VIII inhibitor

(2008) C. L. Kempton et al.   BLOOD

The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate

(2008) Ampaiwan Chuansumrit et al.   BLOOD COAGULATION & FIBRINOLYSIS

Thrombin generation testing in routine clinical practice: are we there yet?

(2008) J. J. van Veen et al.   BRITISH JOURNAL OF HAEMATOLOGY

New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors

(2008) Y. DARGAUD et al.   HAEMOPHILIA

Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations

(2008) J. BOEKHORST et al.   HAEMOPHILIA

Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature

(2008) A. OBERGFELL et al.   HAEMOPHILIA

Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care

(2008) J. M. TEITEL et al.   HAEMOPHILIA

Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors

(2008) E. BERNTORP   HAEMOPHILIA

Plasma and albumin-free recombinant factorVIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients

(2008) V. S. BLANCHETTE et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

(2008) P. W. COLLINS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS